Inogen, Inc. (NASDAQ: INGN) shares began Wednesday lower. The company, a medical technology concern offering innovative respiratory products for use in the homecare setting, today announced financial results for the quarter ended September 30, 2025.
INGN reported $92.4 million revenue, a year-over-year increase of 4.0%, marking the seventh consecutive quarter of mid-single-digit percentage growth. GAAP net loss of $5.3 million and adjusted net loss of $0.5 million compared to prior year GAAP net loss of $6.0 million and adjusted net loss of $2.6 million
It also reported $2.3 million in adjusted EBITDA, the third consecutive quarter of positive adjusted EBITDA
The company also reiterated full year revenue outlook of $354 million to $357 million and raises adjusted EBITDA guidance to approximately $2 million Inogen also initiated a limited market release of the Simeox airway clearance device in the United States
"We continue to make meaningful progress, driving consistent mid-single-digit revenue growth, operational improvements, and strong adjusted EBITDA," said CEO Kevin Smith "This quarter’s results reflect the strength of our commercial strategies, financial discipline, and commitment to delivering innovative solutions. Looking forward, we remain focused on building long-term value for our shareholders by advancing Inogen’s leadership in respiratory care."
INGN shares fell 43 cents, or 5.3%, to $7.63.
Related Stories
